Weekly Docetaxel Versus Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients With Advanced Nonsmall Cell Lung Cancer.

The article compares the efficacy of weekly docetaxel with the combination of docetaxel and gemcitabine in elderly or poor performance status patients with advanced nonsmall cell lung cancer (NSCLC) based on a randomized clinical trial in the U.S. The study involved 350 patients who were randomized and 345 of them received treatment. It found that treatment with docetaxel/gemcitabine produced a modest improvement but had no impact on survival when compared with single-agent weekly docetaxel.